Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Public Trust Indispensable for Industry Development: Mr Futagawa of Health Policy Bureau
January 7, 2015
- Pharmaceutical and Food Safety Bureau to Promote Prescription-to-OTC Switches Based on Industry Opinions
January 6, 2015
- MHLW OKs 31 Products Including Takeda’s Vonoprazan
January 5, 2015
- Ruling Parties Settle on 25%-Plus-5% Cap for R&D Tax Credit
January 5, 2015
- Health Minister Shiozaki Reappointed
December 25, 2014
- LDP Study Group Shows Sense of Crisis over Reduction of R&D Tax Deduction Cap
December 25, 2014
- Integrated Clinical and Epidemiological Research Ethical Guidelines to Take Effect April: MHLW
December 25, 2014
- Deliberations on Specific Cases of Cost-Effective Assessments to Be Closed to the Public: Chuikyo
December 25, 2014
- Investigation Finds No Intentional Data Falsification from J-ADNI Study
December 25, 2014
- MHLW Orders Revision of Package Insert for Jevtana
December 24, 2014
- Novartis Pharma Should Take Thorough Measures to Prevent Worker Involvement in IITs: Health Minister
December 22, 2014
- New “Compassionate Use” System to Be Introduced in FY2015; Will Apply to Industry-Sponsored Trials as well as IITs
December 22, 2014
- Orphan Designation to Be Expanded to Include Intractable Diseases Affecting More than 50,000 Patients
December 22, 2014
- MHLW OKs New Indication for Nesp, Pediatric Dosages for Cancidas
December 19, 2014
- LDP to Begin Intensive Tax Debate from December 25
December 19, 2014
- MHLW Releases Discussion Outline of ICH Lisbon Meeting
December 18, 2014
- LDP Tax Panel Execs Eye Slight Cut of R&D Tax Deduction Cap
December 17, 2014
- Drug Makers Present Cases in Which PI Trials in Japanese Could Be Omitted in Multinational Studies: PMDA Workshop
December 17, 2014
- Japan Tax Reform Plan Will Be Compiled by Year-End: Abe
December 16, 2014
- Editor’s Pick: Five Healthcare News Headlines for Dec. 1 - 14
December 15, 2014
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…